Results 241 to 250 of about 4,942 (259)

Abstract 4366962: Updated Meta-Analysis of Randomized Controlled Trials Evaluating the Safety and Efficacy of Inclisiran in Hyperlipidemia

Circulation
Background: Inclisiran, a small interfering RNA (siRNA), inhibits hepatic PCSK9 synthesis, leading to significant LDL-C reduction. Previous meta-analyses have addressed short-term efficacy; however, recent long-term data warranted an updated ...
Muhammad Waseem Tahir, Junaid Saleem, Arsalan Hyder, Aresha Masood Shah, Amina Akram, Muhammad Mohid Haroon, Izma Kamran Ali, Karthikk Murali, Zubia Tahir   +8 more
semanticscholar   +1 more source

Abstract 4364741: Real-World Assessment of the Efficacy of Inclisiran in Lowering Low-Density Lipoprotein Cholesterol: Outcomes From AAH Tertiary Cardiovascular Clinics

Circulation
Background: Inclisiran is a novel innovative therapy for the reduction of low-density lipoprotein cholesterol (LDL-C). However, real-world data about its efficacy are limited.
P. Hundal, Niloufar Javadi, Kirandeep Kaur, Jim Kanani, Sara Walczak, Venkateswara Gogineni, Eric S. Weiss, John D. Crouch, S. Allaqaband, Tanvir Bajwa, Patrycja Galazka, A. Tajik, M. F. Jan   +12 more
semanticscholar   +1 more source

First case report of inclisiran therapy in a heart transplant patient.

Minerva cardiology and angiology
Transplant coronary artery disease (TCAD) represents a severe complication after heart transplantation, modulated by hypercholesterolemia. Management of dyslipidemia in this setting is complex due to interactions between statins and immunosuppressants ...
Andrea Solano, O. de Filippo, C. Raineri, F. D’Ascenzo, G. D. de Ferrari   +4 more
semanticscholar   +1 more source

Abstract 4358425: VICTORION-INCEPTION: Consistent Low-density Lipoprotein Cholesterol Lowering With Inclisiran Following Acute Coronary Syndrome Independent of Index Lipid-lowering Therapy

Circulation
Background: In the VICTORION-INCEPTION trial (NCT04873934), participants with recent acute coronary syndrome (ACS) randomized to receive inclisiran + usual care had greater low-density lipoprotein cholesterol (LDL-C) reductions and goal attainment ...
Alan Brown, Nihar Desai, Jeffrey L Anderson, J. Muhlestein, S. Sarwat, M. Ramirez, Kirk U Knowlton   +6 more
semanticscholar   +1 more source

Inclisiran jetzt verfügbar

MMW - Fortschritte der Medizin, 2021
openaire   +1 more source

NICE guidance on inclisiran should be reconsidered

BMJ, 2021
Paula, Byrne, Maryanne, Demasi, Susan M, Smith   +2 more
openaire   +2 more sources

Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience.

Progress in cardiovascular diseases
G. Bosco, Francesco Di Giacomo Barbagallo, Maurizio Di Marco, Sabrina Scilletta, Nicoletta Miano, Stefano Esposto, Giovanni Pennisi, Simone Prezzavento, Antonio Gallo, E. M. De Francesco, Roberta Malaguarnera, A. Di Pino, Francesco Purrello, S. Piro, Roberto Scicali   +14 more
semanticscholar   +1 more source

The introduction of inclisiran

Journal of Prescribing Practice, 2021
openaire   +1 more source

Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry.

Cardiovascular Drugs and Therapy
Francesco Briani, Elena Sani, Gabriele Venturi, Francesco Bacchion, Sara Balzano, M. Battocchio, Katia D'Elia, Giulia Maria Frigo, Luca Licchelli, Antonio Lupo, A. Marangoni, Luigi Rivetti, Mauro Scanferlato, Sabina Zambon, M. Zenti, Elisabetta Rinaldi, A. Mugnolo   +16 more
semanticscholar   +1 more source

Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China

Applied Health Economics and Health Policy
Pengpeng Wang, Le Liang, Yamei Li
semanticscholar   +1 more source